ES2063914T3 - Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso. - Google Patents

Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso.

Info

Publication number
ES2063914T3
ES2063914T3 ES90301212T ES90301212T ES2063914T3 ES 2063914 T3 ES2063914 T3 ES 2063914T3 ES 90301212 T ES90301212 T ES 90301212T ES 90301212 T ES90301212 T ES 90301212T ES 2063914 T3 ES2063914 T3 ES 2063914T3
Authority
ES
Spain
Prior art keywords
cell lines
packaging
defectuous
hiv provirus
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301212T
Other languages
English (en)
Inventor
Joseph Sodroski
William A Haseltine
Heinrich Gottlinger
Andrew Lever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2063914T3 publication Critical patent/ES2063914T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ES DESCUBIERTO UN VECTOR HIV DEFECTUOSO DE EMPAQUETADO. ESTE VECTOR PUEDE SER USADO PARA ESTABLECER LAS LINEAS CELULARES DEFECTUOSAS DE EMPAQUETADO. ESTAS LINEAS CELULARES PUEDEN SER USADAS EN DESARROLLAR UNA VACUNA, ANTICUERPOS HIV Y COMO PARTE DE UN SISTEMA PARA TRANSFERENCIA DE GEN.
ES90301212T 1989-02-06 1990-02-06 Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso. Expired - Lifetime ES2063914T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30766489A 1989-02-06 1989-02-06

Publications (1)

Publication Number Publication Date
ES2063914T3 true ES2063914T3 (es) 1995-01-16

Family

ID=23190695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301212T Expired - Lifetime ES2063914T3 (es) 1989-02-06 1990-02-06 Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso.

Country Status (7)

Country Link
EP (1) EP0386882B1 (es)
JP (1) JP3140757B2 (es)
AT (1) ATE111529T1 (es)
CA (1) CA2009403C (es)
DE (1) DE69012379T2 (es)
DK (1) DK0386882T3 (es)
ES (1) ES2063914T3 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
EP1645635A3 (en) * 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
CA2067778A1 (en) * 1989-10-16 1991-04-17 The Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
ES2052478T1 (es) * 1989-11-20 1994-07-16 Oncogen Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
CA2092195C (en) * 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
ES2150416T3 (es) * 1990-09-25 2000-12-01 Cantab Pharma Res Vacuna virica defectiva producida por una linea celular complementada en trans.
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
CN1062601C (zh) * 1992-03-24 2001-02-28 剑桥药物研究有限公司 病毒疫苗
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
EP1770168A3 (en) * 1993-01-26 2009-05-06 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions and methods for delivery of genetic material
WO1995004546A1 (en) * 1993-08-06 1995-02-16 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
JP5102414B2 (ja) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 髄膜炎菌抗原および組成物
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
EP1141331B1 (en) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
CN100392082C (zh) 1999-04-30 2008-06-04 启龙股份公司 保守的奈瑟球菌抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1416352B (zh) 2000-01-17 2011-05-25 启龙股份公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
CA2629376C (en) 2005-11-14 2015-06-09 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
RU2609769C2 (ru) 2011-04-06 2017-02-02 Биоваксим Лимитед Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒

Also Published As

Publication number Publication date
DE69012379T2 (de) 1995-03-09
ATE111529T1 (de) 1994-09-15
DK0386882T3 (da) 1994-12-12
CA2009403C (en) 2000-10-31
CA2009403A1 (en) 1990-08-06
EP0386882A1 (en) 1990-09-12
DE69012379D1 (de) 1994-10-20
JPH0361492A (ja) 1991-03-18
JP3140757B2 (ja) 2001-03-05
EP0386882B1 (en) 1994-09-14

Similar Documents

Publication Publication Date Title
ES2063914T3 (es) Provirus hiv defectuoso para el empaquetamiento, lineas celulares y su uso.
ES2091777T3 (es) Procedimiento para preparar un ensayo inmunologico de transferencia western.
NO871785D0 (no) Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse.
SE8802818D0 (sv) Anordning for stapling av satsvis anordnade foremal
ES2032194T3 (es) Solubilizacion de agregados proteicos.
IT8022740A0 (it) Procedimento per la produzione di etanolo in forte concentrazione impiegando microorganismi immobilizzati.
DE3779905D1 (de) Zellkulturtraeger.
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
Holtermann et al. The development of soluble (S) and viral (V) antigens of influenza A virus in tissue culture as studied by the fluorescent antibody technique. 1. Studies employing a low multiplicity of infection in beef embryo kidney cells
ATE294240T1 (de) Verfahren und kit, um biologische substanzen in plasmamembran und/oder zytosol einzuführen
AR220838A1 (es) Procedimiento para preparar una vacuna de virus de influenza(gripe);procedimiento de propagacion de virus de influenza y cultivo liquido de celulas inoculadas con dicho virus,de aplicacion exclusiva en dicho procedimiento para preparar dicha vacuna
ATE54757T1 (de) Verfahren zum nachweis von htlv-iii neutralisierenden antikoerpern in sera.
ES450075A1 (es) Un metodo de preparacion de derivados de bis-triazinilamino-estilbeno.
DK280190A (da) Amfifile peptider og praeparater indeholdende saadanne
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
GB765552A (en) Improvements in or relating to apparatus for facilitating the handling of drums and like containers
JPS5213478A (en) Process for dissolving of hard-soluble gas and a gas dissolving appara tus used in said process
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
MY100476A (en) Supported viral antigen and preparation and use thereof
SU940700A1 (ru) Удмуртский способ осветлени в смешанных молодн ках естественного происхождени
SE406921B (sv) Biologiskt aktivt material av ett enzym, en kofaktor en inhibitor ett antigen eller antikropp, kopplat till en organisk polymer samt forfarandet for framstellning herav
JPS5254019A (en) Method of making biological preparations
FI905055A0 (fi) Ett p1-bakteriofagkloningssystem foer sao stora dna-fragment som 95 kb.
ES2056858T3 (es) Esplenopentinas aciladas modificadas, procedimiento para su fabricacion y su uso.
ECSP014147A (es) Tecnica de trasfecciòn intensificada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 386882

Country of ref document: ES